News Releases

News Releases

Date Title
Nov 07, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 05, 2018
Summary ToggleOpiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Nov 01, 2018
Summary ToggleOpiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
Oct 29, 2018
Summary ToggleOpiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
Oct 22, 2018
Summary ToggleOpiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
Oct 18, 2018
Summary ToggleOpiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
Sep 28, 2018
Summary ToggleOpiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 26, 2018
Summary ToggleOpiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Sep 25, 2018
Summary ToggleOpiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Sep 24, 2018
Summary ToggleOpiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
Sep 20, 2018
Summary ToggleOpiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
Sep 10, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Sep 04, 2018
Summary ToggleOpiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
Aug 09, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Aug 02, 2018
Summary ToggleOpiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
Jun 25, 2018
Summary ToggleOpiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Jun 12, 2018
Summary ToggleOpiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Jun 04, 2018
Summary ToggleOpiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
May 29, 2018
Summary ToggleOpiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
May 08, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 03, 2018
Summary ToggleOpiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Apr 18, 2018
Summary ToggleOpiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Mar 19, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
Mar 07, 2018
Summary ToggleOpiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
Feb 12, 2018
Summary ToggleOpiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Feb 08, 2018
Summary ToggleOpiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
Jan 02, 2018
Summary ToggleOpiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants